Capricor Therapeutics' (CAPR) "Neutral" Rating Reiterated at Roth Capital

Key Points

• Roth Capital reiterated its Neutral rating on Capricor Therapeutics and raised its price target from $7.00 to $10.50, implying 12.41% upside from the prior close.
• Analyst views are mixed: five rate the stock Buy, five Hold, and one Sell; the consensus rating is Hold, with an average price target of $30.09.
• Capricor reported a quarterly loss of $0.73 per share, wider than analysts’ expected loss of $0.44, while the stock opened at $9.34 on Friday.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report)'s stock had its "neutral" rating reissued by Roth Capital in a research note issued to investors on Friday, Benzinga reports. They presently have a $10.50 price objective on the biotechnology company's stock, up from their previous price objective of $7.00. Roth Capital's target price points to a potential upside of 12.41% from the company's previous close.

Several other research firms have also recently commented on CAPR. Maxim Group cut Capricor Therapeutics from a "buy" rating to a "hold" rating in a research note on Thursday, July 30th. Piper Sandler upgraded Capricor Therapeutics from a "neutral" rating to an "overweight" rating in a report on Tuesday, September 1st. Ladenburg Thalmann & Co. Inc. downgraded shares of Capricor Therapeutics from a "buy" rating to a "neutral" rating in a research report on Thursday, July 30th. HC Wainwright downgraded shares of Capricor Therapeutics from a "buy" rating to a "neutral" rating in a research report on Monday, July 27th. Finally, Oppenheimer restated an "outperform" rating on shares of Capricor Therapeutics in a report on Thursday, October 8th. Five research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Hold" and an average price target of $30.09.

Capricor Therapeutics Stock Down 8.8%

CAPR opened at $9.34 on Friday. Capricor Therapeutics has a twelve month low of $2.96 and a twelve month high of $40.37. The company has a fifty day moving average of $8.10 and a 200-day moving average of $19.92. The stock has a market cap of $543.09 million, a PE ratio of -3.52 and a beta of 0.80.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last issued its quarterly earnings results on Tuesday, November 10th. The biotechnology company reported ($0.73) earnings per share for the quarter, missing analysts' consensus estimates of ($0.44) by ($0.29). Sell-side analysts anticipate that Capricor Therapeutics will post -1.71 EPS for the current fiscal year.

Hedge Funds Weigh In On Capricor Therapeutics

A number of large investors have recently modified their holdings of the company. Russell Investments Group Ltd. raised its holdings in shares of Capricor Therapeutics by 21.2% in the 3rd quarter. Russell Investments Group Ltd. now owns 17,326 shares of the biotechnology company's stock worth $164,000 after acquiring an additional 3,036 shares during the last quarter. Commonwealth Equity Services LLC boosted its stake in Capricor Therapeutics by 151.7% during the 3rd quarter. Commonwealth Equity Services LLC now owns 67,402 shares of the biotechnology company's stock valued at $638,000 after purchasing an additional 40,627 shares during the last quarter. VestGen Advisors LLC acquired a new position in Capricor Therapeutics during the 3rd quarter valued at about $191,000. Oppenheimer & Co. Inc. boosted its stake in Capricor Therapeutics by 169.1% during the 3rd quarter. Oppenheimer & Co. Inc. now owns 203,781 shares of the biotechnology company's stock valued at $1,930,000 after purchasing an additional 128,067 shares during the last quarter. Finally, SBI Securities Co. Ltd. increased its holdings in Capricor Therapeutics by 834.6% during the 3rd quarter. SBI Securities Co. Ltd. now owns 26,310 shares of the biotechnology company's stock worth $249,000 after purchasing an additional 23,495 shares in the last quarter. 21.68% of the stock is currently owned by institutional investors.

Capricor Therapeutics Company Profile

Capricor Therapeutics is a biotechnology company developing cell- and exosome-based therapies for serious diseases. Its research focuses on using these technologies to address conditions with limited treatment options. The company's leading program is deramiocel, also known as CAP-1002, an investigational therapy made from donor-derived cardiac cells. Capricor is developing it for Duchenne muscular dystrophy, a rare genetic disorder that causes progressive muscle weakness. Capricor is also advancing an exosome-based technology platform for potential therapeutic applications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.